Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.

Become a member or log in to add this story to your CPD history

World Bee Day celebrations begin

News Story 1
 Today (20 May) marks the fifth annual World Bee Day, which raises awareness of the importance of bees and pollinators to people and the planet. Observed on the anniversary of pioneering Slovenian beekeeper Anton Jana's birthday, this year's celebration is themed: 'Bee Engaged: Celebrating the diversity of bees and beekeeping systems'.

Organisations and people celebrating the day will raise awareness of the accelerated decline in pollinator diversity, and highlight the importance of sustainable beekeeping systems and a wide variety of bees. Slovenia, the initiator of World Bee Day, will be focusing on teaching young people about the significance of pollinators. 

Click here for more...
News Shorts
Further avian flu cases confirmed

Three cases of highly pathogenic avian influenza (HPAI) H5N1 have been confirmed in recent days, bringing the total number of cases in England to 98.

On Thursday, the APHA confirmed two cases of HPAI H5N1 near Redgrave, Mid Suffolk and Market Weston, West Suffolk. A case H5N1 was also confirmed in poultry at a premises near Southwell, Newark and Sherwood, Nottinghamshire.

Protection and surveillance zones are in place around the affected premises. Further details are available at